UBS Group’s Cogentix Medical, Inc. CGNT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q2
Sell
-12,512
Closed -$48K 8586
2018
Q1
$48K Buy
+12,512
New +$39.2K ﹤0.01% 5753
2017
Q4
Sell
-2,427
Closed -$6K 8346
2017
Q3
$6K Sell
2,427
-4,156
-63% -$9.11K ﹤0.01% 7187
2017
Q2
$11K Sell
6,583
-2,076
-24% -$3.56K ﹤0.01% 6748
2017
Q1
$16K Buy
8,659
+7,277
+527% +$14.4K ﹤0.01% 6334
2016
Q4
$3K Sell
1,382
-2,010
-59% -$4.11K ﹤0.01% 7465
2016
Q3
$6K Buy
3,392
+2,004
+144% +$2.59K ﹤0.01% 7096
2016
Q2
$1K Buy
+1,388
New +$1.37K ﹤0.01% 7619
2016
Q1
Sell
-821
Closed -$1K 8549
2015
Q4
$1K Sell
821
-5,134
-86% -$7.02K ﹤0.01% 8222
2015
Q3
$7K Buy
5,955
+1,009
+20% +$1.55K ﹤0.01% 7541
2015
Q2
$8K Buy
+4,946
New +$8.1K ﹤0.01% 7641

UBS Group's CGNT Position: Q2 2018 in Review

UBS Group sold out of Cogentix Medical, Inc. (CGNT) in Q2 2018, closing a stake of 12,512 shares — an estimated $48K sold.

UBS Group first reported a position in CGNT in Q2 2015 and held it in 10 quarters. The position peaked at $48K in Q1 2018. 0 funds tracked by Wall St. Rank hold CGNT as of Q2 2018.

  • UBS Group reported no remaining Cogentix Medical, Inc. position as of Q2 2018 after selling out during the quarter.
  • UBS Group sold 12,512 Cogentix Medical, Inc. shares in Q2 2018, an estimated $48K.
  • UBS Group first reported a position in Cogentix Medical, Inc. in Q2 2015 and held it in 10 quarters.
  • UBS Group's Cogentix Medical, Inc. position peaked at $48K in Q1 2018.
  • 0 funds tracked by Wall St. Rank held Cogentix Medical, Inc. as of Q2 2018.

Based on UBS Group's 13F filing for Q2 2018, filed 14 Aug 2018.